Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035261 | 0.89 | PAK1 (0.43) | PAK1PAK2PAK4PKN1RIPK2 | |
| SCHEMBL15035254 | 0.88 | PAK1 (0.42) | PAK1PAK2PAK4PKN1RIPK2 | |
| SCHEMBL15035259 | 0.88 | PAK4 (0.42) | PAK1PAK2PAK4PKN1RIPK2 | |
| SCHEMBL15035268 | 0.82 | PAK1 (0.55) | PAK1PAK2PAK4PKN1RIPK2 | |
| SCHEMBL15035252 | 0.80 | PAK1 (0.43) | PAK1PAK2RIPK2NOD2TNK2 | |
| SCHEMBL15035255 | 0.80 | PAK1 (0.42) | PAK1PAK2RIPK2NOD2TNK2 | |
| SCHEMBL15035248 | 0.76 | CDK4 (0.41) | RIPK2NOD2TNK2 | |
| SCHEMBL15035573 | 0.76 | RIPK2 (0.40) | PAK1PAK2PAK4PKN1RIPK2 | |
| SCHEMBL13554002 | 0.76 | PKN1 (0.54) | PAK1PAK2PAK4PKN1 | |
| SCHEMBL15035445 | 0.75 | RIPK2 (0.43) | PAK1PAK2PAK4PKN1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PAK2 2/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.